Stock Analysis
Boston Scientific Corp.BSX
P/E 17.51×· 5Y range 16.40–122.28×· bottom 2% of history
Sector: Healthcare · Industry: Medical Devices
AnalystsStrong Buy38 analystsP/E 17.5× sits at the 2nd percentile of its 5.0978781656399725-year history.
Cash covers 4% of debt · Q2 2026.
PMP Verdict
Strong business, attractive price
Strengths
- Growth90
- Quality84
High-quality business at an attractive price.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Revenue CAGR 14.0% — durable top-line growth
- ✓Interest coverage 12.3× — debt well covered
- ✓P/E 17.5× at bottom 2% of 5-year history
What's happening with BSX
Profile
Strong growth, earnings quality and valuation; moat lags behind.
How is each axis scored?
- Valuation77/100 · Strong
- P/E vs own history (2th pct)25/25
- FCF yield (5.7%)20/25
- P/S (3.1x)20/25
- EV/EBIT (18.3x)12/25
- Growth90/100 · Strong
- Revenue CAGR (14.0%)20/25
- Net income CAGR (31.0%)25/25
- EPS CAGR 5Y (29.6%)25/25
- Fwd implied growth (27.6%)20/25
- Profitability64/100 · Moderate
- ROIC (8.8%)12/25
- ROE (14.6%)12/25
- Net margin (17.5%)20/25
- Operating margin (19.8%)20/25
- Financial Health67/100 · Moderate
- Altman Z (2.65)18/25
- Current ratio (1.24)12/25
- Interest coverage (12.3x)25/25
- Net cash / debt (D/A 27%)12/25
- Quality84/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.42)20/25
- FCF conversion (99%)22/25
- Margin stability (σ 6.0%)20/25
- Moat48/100 · Weak
- ROIC >12% years (0/10 yrs)0/25
- Median gross margin (69.3%)25/25
- FCF-positive years (9/10 yrs)18/25
- Worst-year net margin (worst -1.2%)5/25
About Boston Scientific Corp.
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. Show more
It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Headquarters: MARLBOROUGH, MA · Employees: 59,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
77B+P/E (TTM)17.4xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 16.4x–122.3x · 2nd pct
P/FCF17.6xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield5.7%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 0.8%–6.0% · 97th pct
P/S (TTM)3.05xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 2.9x–10.4x · 2nd pct
EV/EBIT18.3xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 17.3x–148.6x · 3rd pct
EV/Sales3.6xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E13.7xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.54xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.38A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.00%B
Grade B: NoneTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
64BROIC8.8%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE14.6%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA8.3%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin17.5%A
Grade A: HighNet Income / Revenue
Operating Margin19.8%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin69.9%A
Grade A: PremiumGross Profit / Revenue
FCF Margin17.3%A
Grade A: HighFCF / Revenue
True FCF Margin15.7%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
90A+Revenue CAGR14.0%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR31.0%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)29.6%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth27.6%C
Grade C: MedAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+1.2%B
Grade B: FlatShare count change over 5Y
SBC / Net Income8.7%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.5%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
67BAltman Z-Score2.65C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.24xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.68xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage12.3xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment3.3yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT2.9xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity0.50xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.04xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
84APiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.42A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion98.7%A
Grade A: StrongFCF / Net Income
Margin Stability6.0%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue4.3%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.48xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
O'Connor Padraig Andrew Filed | O'Connor Padraig Andrew | Option exercise | -1171 | |
O'Connor Padraig Andrew Filed | O'Connor Padraig Andrew | Tax withholding | -567 | |
O'Connor Padraig Andrew Filed | O'Connor Padraig Andrew | Option exercise | +1.2K | |
Morano Susan E Filed | Morano Susan E | BuyOpen market buy | +2.0K | |
Woodworth Emily Filed | Woodworth Emily | BuyI | +2.9K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Monson Jonathan Filed | Monson Jonathan | BuyI | +9.9K | |
Habiger David C Filed | Habiger David C | BuyOpen market buy | +2.1K | |
Habiger David C Filed | Habiger David C | BuyOpen market buy | +140 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
48D+ROIC >12% Years0/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)69.3%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years9/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-1.2%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$2.54
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$0.37
Cash & short-term investments per share (Finnhub)
Book Value / Share$17.23
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$12.62B
Total debt obligations (short + long term)
Cash & Equiv.$539.00M
Cash and short-term investments
Net Debt$12.09B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$25.17B
Shareholders' equity (book value)
Asset / Liability2.26xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$64.06B
Current Market Capitalization
Beta0.59B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Boston Scientific Corp. (BSX)
BSX is up 0.57% at the last close. Boston Scientific Corp. meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 2.65 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.42 suggests a low likelihood of earnings manipulation.
- Boston Scientific Corp. converts about 17% of revenue into free cash flow — strong cash generation.
- Takes ~3.3 years to repay net debt from free cash flow.
- Boston Scientific Corp. posted a net loss in 1 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 77/100, BSX trades near the cheapest end of its own historical range (P/E 17.4).
See how BSX ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all BSX moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 44.12 | +2.59% | 2.06 |
| Oct 15 | After-hours | 44.14 | +2.65% | 2.10 |
| Oct 12 | Regular | 43.67 | +2.20% | 2.01 |
| Oct 12 | After-hours | 43.84 | +2.60% | 2.32 |
Frequently Asked Questions about BSX
What is the current Boston Scientific Corp. (BSX) stock price?
BSX is trading at $44.39 at the last market close, up 0.57% on the session. PreMarketPrice tracks BSX pre-market, intraday and after-hours prices.
Is BSX stock a buy right now?
PreMarketPrice's quantitative model rates Boston Scientific Corp.'s financial health at 67/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is BSX stock overvalued?
Boston Scientific Corp. trades at a trailing P/E of 17.4 and our valuation score rates it 77/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Boston Scientific Corp. report earnings?
No confirmed earnings date is currently scheduled for BSX. The Earnings section lists recent reports and updates as dates are announced.
What sector does Boston Scientific Corp. operate in?
Boston Scientific Corp. operates in the Healthcare sector, within the Medical Devices industry. The Related Stocks section lists sector peers for comparison.
What does Boston Scientific Corp. do?
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts.
About Boston Scientific Corp. (BSX) Stock
Boston Scientific Corp. (BSX) is a US-listed stock operating in the Healthcare sector, specifically the Medical Devices industry. As of the latest update, Boston Scientific Corp. is trading at $44.39, up 0.57% on the day with a market capitalization of $64.1 billion. The financial health score for BSX is 67/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BSX stock.
BSX Stock Analysis & Key Metrics
On PreMarketPrice, you can track Boston Scientific Corp. (BSX) across multiple dimensions:
- Pre-market price & movement: Real-time BSX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BSX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Boston Scientific Corp. across multiple reporting periods.
- Financial health score: A composite score of 67/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BSX.
- Sector peers: Compare BSX against 6 other healthcare stocks on key financial metrics.
Is BSX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Boston Scientific Corp. (BSX) as an investment. The financial health score of 67/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Boston Scientific Corp. (BSX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.